Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes: A possible protective mechanism against atherothrombosis

Thrombosis and Haemostasis

Volumn 84, Issue 4, 2000, Pages 680-688

  Ganne, F ^a   Vasse, M ^a   Beaudeux, J L ^a   Peynet, J ^a   Francois, A ^a   Mishal, Z ^a   Chartier, A ^a   Tobelem, G ^a   Vannier, J P ^a   Soria, J ^a   Soria, C ^a  

^a UNIVERSITÉ DE ROUEN   (France)

Author keywords

Atherothrombosis; HMG CoA reductase inhibitor; Metalloproteinase; Monocyte; Urokinase

Indexed keywords

CERIVASTATIN; FARNESYL DIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMIN; PROTEIN SUBUNIT; PYROPHOSPHORIC ACID DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL FUNCTION; CELL NUCLEUS; CELLULAR DISTRIBUTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; LIPID TRANSPORT; MONOCYTE; NORMAL HUMAN; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS;

EID: 0033793763     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614087     Document Type: Article

References (32)

1. The incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study
2. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
3. Statins do more that just lower cholesterol
4. Coronary plaque disruption
5. The unstable atheroma
6. Plaque fissuring. The cause of acute myocardial infarction, sudden ischemic death and crescendo angina
7. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
8. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymatic properties
9. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
10. Characterisation of plasminogen activation by glycophosphatidylinositol-anchored urokinase
11. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
12. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries
13. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins. Consequences for plasmin generation and monocyte adhesion
14. Identification of the urokinase receptor as an adhesion receptor for vitronectin
15. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
16. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition
17. Macrophage infiltration in acute coronary syndrome: Implications for plaque rupture
18. Cytosqueleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway
19. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis
20. Uptake of oxidised LDL by macrophages differs from that of acetyl LDL and leads to expansion of an acidic endolysosomal compartment
21. Leukocyte typing V: White cells differentiation antigens
22. Activation of the 92 kDa type IV collagenase by tissue kallikrein
23. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
24. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages
25. Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1
26. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA
27. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells
28. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B
29. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
30. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherosclerosis
31. The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and participates in the activation of NF-kappa B
32. Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways